Patents Examined by Karlheinz R. Skowronek
  • Patent number: 10376560
    Abstract: This invention relates to aqueous solution compositions of vancomycin that are stable, ready for use and do not require reconstitution.
    Type: Grant
    Filed: July 13, 2017
    Date of Patent: August 13, 2019
    Assignee: LATITUDE PHARMACEUTICALS, INC.
    Inventor: Andrew Xian Chen
  • Patent number: 10370434
    Abstract: The invention relates to a Myc dominant negative mutant, called Omomyc, for use in medicine and for use in the prevention and/or treatment of cancer. The invention also refers to a fusion protein comprising Omomyc and pharmaceutical composition thereof and their use in medicine and, in particular, for treatment of cancer.
    Type: Grant
    Filed: May 7, 2014
    Date of Patent: August 6, 2019
    Assignee: FUNDACIÓ PRIVADA INSTITUT D'INVESTIGACIÓ ONCOLÒGICA DE VALL HEBRON
    Inventors: Laura Soucek, Marie-Eve Beaulieu
  • Patent number: 10369284
    Abstract: The invention concerns a kit and a syringe for use in a therapeutic method for intracutaneous filling of the collagen structure in connective tissue of the skin, and the use thereof, particularly as part of the treatment of skin defects, particularly skin diseases and signs of skin aging.
    Type: Grant
    Filed: July 15, 2013
    Date of Patent: August 6, 2019
    Assignee: MEIDRIX BIOMEDICALS GMBH
    Inventor: Thomas Graeve
  • Patent number: 10363320
    Abstract: The present invention relates to a conjugate comprising oxyntomodulin, an immunoglobulin Fc region, and non-peptidyl polymer wherein the conjugate being obtainable by covalently linking oxyntomodulin to immunoglobulin Fc region via non-peptidyl polymer, and a pharmaceutical composition for the prevention or treatment of obesity comprising the conjugates. The conjugate comprising oxyntomodulin and the immunoglobulin Fc of the present invention reduces food intake, suppresses gastric emptying, and facilitates lipolysis without side-effects, unlike native oxyntomodulin, and also shows excellent receptor-activating effects and long-term sustainability, compared to native oxyntomodulin. Thus, it can be widely used in the treatment of obesity with safety and efficacy.
    Type: Grant
    Filed: June 28, 2017
    Date of Patent: July 30, 2019
    Assignee: Hanmi Science Co., Ltd.
    Inventors: Sung Youb Jung, Dae Jin Kim, Sung Hee Park, Young Eun Woo, In Young Choi, Se Chang Kwon
  • Patent number: 10351596
    Abstract: STAT3 hyperphosphorylation, dimerization and DNA binding are required for its ability to contribute to malignant transformation. As such, STAT3 has been recognized as a promising target for cancer therapy. Although a number of inhibitors of STAT3-STAT3 dimerization have been reported, molecular ligands that prevent interactions between STAT3 and DNA are very rare. The ?-AApeptide-based one-bead-one-compound (OBOC) combinatorial library was used, and identified ?-AApeptides that can selectively inhibit STAT3/DNA interaction and suppress the expression levels of STAT3 target genes in intact cells. The results not only validate ?-AApeptides as novel inhibitors of STAT3 signaling pathway, but also demonstrate that in addition to the SH2 domain, the DNA binding domain of STAT3 is targetable for the development of new generation of anti-cancer therapeutics. This also validates the approach of OBOC combinatorial library for the identification of ligands targeting traditionally recognized “undruggable targets”.
    Type: Grant
    Filed: April 26, 2018
    Date of Patent: July 16, 2019
    Assignees: H. Lee Moffitt Cancer Center and Research Institute, Inc., University of South Florida
    Inventors: Said M. Sebti, Jianfeng Cai
  • Patent number: 10351603
    Abstract: Synthetic nanostructures, polypeptides that are useful, for example, in making synthetic nanostructures, and methods for using such synthetic nanostructures are disclosed herein.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: July 16, 2019
    Assignee: University of Washington
    Inventors: David Baker, Jacob B. Bale, Neil P. King, William H. Sheffler, Daniel Ellis
  • Patent number: 10350162
    Abstract: This invention provides compositions comprising a byetta, fish oil, and a protease inhibitor, method for treating diabetes mellitus, comprising administering same, and methods for oral or rectal administration of a byetta.
    Type: Grant
    Filed: April 2, 2013
    Date of Patent: July 16, 2019
    Assignee: Oramed Ltd.
    Inventor: Miriam Kidron
  • Patent number: 10350150
    Abstract: Compositions and methods for administering collagen to a human subject have been developed. The collagen-containing lipid vesicles of the invention provide a delivery system for human collagen which eliminates problems associated with chemical and physical instability of the collagen as well as immune responses to non-human collagen.
    Type: Grant
    Filed: February 11, 2015
    Date of Patent: July 16, 2019
    Inventor: Mark A. Pinsky
  • Patent number: 10335489
    Abstract: A composition in the form of an injectable aqueous solution, the pH of which is between 6.0 and 8.0, including at least (a) a basal insulin, the isoelectric point pI of which is between 5.8 and 8.5; and (b) a co-polyamino acid bearing carboxylate charges and substituted with hydrophobic radicals. In one embodiment, the compositions also include a prandial insulin and/or a gut hormone.
    Type: Grant
    Filed: October 26, 2015
    Date of Patent: July 2, 2019
    Assignee: ADOCIA
    Inventor: Olivier Soula
  • Patent number: 10336803
    Abstract: This document provides methods and materials related to insulin secreting polypeptides. For example, polypeptides having the ability to induce insulin secretion and methods and materials for using use such polypeptides to induce insulin secretion and to treat diabetes are provided.
    Type: Grant
    Filed: March 22, 2018
    Date of Patent: July 2, 2019
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Horng H. Chen, John C. Burnett, Jr.
  • Patent number: 10335448
    Abstract: Provided herein are compositions and methods for treating or preventing fibrosis.
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: July 2, 2019
    Assignee: The UAB Research Foundation
    Inventors: Philip J. O'Reilly, Edwin J. Blalock
  • Patent number: 10328116
    Abstract: The present invention relates to a combination comprising a proteasome inhibitor and a cyclic peptide that comprises an exposed Arg-Gly-Asp (RGD) moiety. In particular, the present invention relates to a combination comprising a proteasome inhibitor selected from the group consisting of: a boronate, an epoxyketone, a peptide aldehyde and a ?-lactone protease inhibitor; and a cyclic peptide that comprises an exposed Arg-Gly-Asp (RGD) moiety. More particularly, the present invention relates to a combination comprising a proteasome inhibitor selected from the group consisting of: bortezomib, delanzomib, ixazomib, carfilzomib, oprozomib, MG132 and marizomib; and a cyclic peptide that comprises an exposed Arg-Gly-Asp (RGD) moiety.
    Type: Grant
    Filed: October 27, 2015
    Date of Patent: June 25, 2019
    Assignee: BIG DNA LTD
    Inventors: John Bernard March, Ewan McIntosh Clark
  • Patent number: 10329327
    Abstract: The invention is directed to a composition comprising all or a portion of a beta-tricalcium phosphate (?-TCP) bound to all or a portion of a ?-TCP binding peptide and methods of use thereof.
    Type: Grant
    Filed: December 6, 2011
    Date of Patent: June 25, 2019
    Assignee: Massachusetts Institute of Technology
    Inventors: Luis Alvarez, Linda G. Griffith, Yadir Guerrero, Linda Stockdale, Jaime Rivera
  • Patent number: 10329341
    Abstract: Novel collagen mimics are disclosed with a tripeptide unit having the formula (Xaa-Yaa-Gly)n,where one of the positions Xaa or Yaa is a bulky, non-electron withdrawing proline derivative. By substituting a proline derivative at either the Xaa or Yaa position in the native collagen helix, the stability of the helix is increased due solely to steric effects relative to prior known collagen-related triple helices. Methods are also disclosed for making the novel collagen mimics.
    Type: Grant
    Filed: August 2, 2017
    Date of Patent: June 25, 2019
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Ronald T. Raines, Matthew D. Shoulders, Jonathan A. Hodges
  • Patent number: 10323062
    Abstract: The present invention relates to a peptide separated from the fraction of oyster enzyme hydrate displaying the ability of suppressing angiotensin converting enzyme (ACE) and a pharmaceutical composition for the prevention and treatment of cardiovascular disease comprising the said peptide as an active ingredient. Particularly, the peptide separated from the fraction of the oyster enzyme hydrate of the present invention significantly inhibits ACE activity, and thus brings blood pressure regulating effect and antihypertensive effect. Therefore, the fraction of the oyster enzyme hydrate of the invention or the peptide separated from the same can be effectively used as an active ingredient of a pharmaceutical composition for the prevention or treatment of cardiovascular disease.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: June 18, 2019
    Assignees: UNIVERSITY-INDUSTRY COOPERATION GROUP OF KYUNG HEE UNIVERSITY, INDUSTRY-ACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSITY
    Inventors: Se-Young Choung, Yeung Joon Choi
  • Patent number: 10322998
    Abstract: Disclosed are isolated, unnatural polypeptides containing cyclically-constrained ?-amino acid residues and cyclically-constrained ?-amino acid residues. The compounds are unnatural and because they contain rotationally constrained residues that are not amenable to enzymatic degradation, the compounds are useful to probe protein-protein and other large molecule interactions.
    Type: Grant
    Filed: November 16, 2010
    Date of Patent: June 18, 2019
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Samuel H. Gellman, Ahlke Hayen, Margaret A. Schmitt, Felix N. Ngassa
  • Patent number: 10323121
    Abstract: Disclosed is a method of making ?-polypeptides. The method includes polymerizing ?-lactam-containing monomers in the presence of a base initiator and a co-initiator which is not a metal-containing molecule to yield the product ?-polypeptides. Specifically disclosed are methods wherein the base initiator is potassium t-butoxide, lithium bis(trimethylsilyl)amide (LiN(TMS)2), potassium bis(trimethyl-silyl)amide, and sodium ethoxide, and the reaction is carried out in a solvent such as chloroform, dichloromethane, dimethylsulfoxide, or tetrahydrofuran.
    Type: Grant
    Filed: May 15, 2017
    Date of Patent: June 18, 2019
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Shannon S. Stahl, Samuel H. Gellman, Sarah E. Lee, Mehmet F. Ilker, Bernard Weisblum, Denis Kissounko
  • Patent number: 10322206
    Abstract: The present invention relates, in part, to sutures which promote wound closure and/or healing. In particular, the present invention provides fibrin microthread sutures that mimic the mechanical behavior of a target tissue thereby reducing, for example, scarring, inflammation, and cell death at the ligature site, including monofilament sutures.
    Type: Grant
    Filed: March 29, 2017
    Date of Patent: June 18, 2019
    Assignee: Worcester Polytechnic Institute
    Inventors: George Pins, Glenn Gaudette, Adam Collette, William Edelman
  • Patent number: 10323065
    Abstract: A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has glioblastoma and/or gastric cancer. A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the glioblastoma and/or gastric cancer.
    Type: Grant
    Filed: February 13, 2019
    Date of Patent: June 18, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Toni Weinschenk, Steffen Walter, Jens Fritsche, Colette Song, Harpreet Singh
  • Patent number: 10322170
    Abstract: The invention discloses a hemostatic composition comprising: a) a biocompatible polymer in particulate form suitable for use in hemostasis, and b) one hydrophilic polymeric component comprising reactive groups.
    Type: Grant
    Filed: March 24, 2016
    Date of Patent: June 18, 2019
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Heinz Gulle, Joris Hoefinghoff, Andreas Goessl, Katarzyna Gorna